Crinetics Pharmaceuticals celebrates FDA approval of Palsonify, the first oral treatment for acromegaly, enhancing patient ...

Paltusotine (Palsonify; Crinetics), a novel nonpeptide somatostatin receptor type 2 nonpeptide (SST2) agonist, was approved by the FDA for the treatment of acromegaly in adults who had an inadequate ...

The FDA has approved Palsonify™ (paltusotine) for adults with acromegaly who did not respond adequately to surgery or are not ...

PALSONIFY™ (paltusotine) INDICATION: PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom ...

Crinetics’ PALSONIFY wins FDA approval as a new oral treatment for acromegaly, offering rapid, effective symptom control.

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...

Good morning. The government is shut down, but the First Opinion Podcast is back. Take a listen.

The Therapeutic Goods Administration has warned Australians to check the brand of melatonin they may be taking and to stop ...

Three years ago, the Detroit Lions made a blockbuster move to trade up and take Jameson Williams in the 2022 NFL Draft. On Saturday, Sept. 6, they signed him to a three-year contract extension on the ...

There’s no appetite in Washington, D.C. to extend a Dec. 31, 2026 deadline to spend about $104 million in federal American Rescue Plan funds, according to Del. James Moylan. Moylan spoke about the ARP ...